Pharmafile Logo

News and Press Releases

atai Life Sciences Announces Update on Beckley Psytech’s phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from phase 1 and First Patients Dosed in phase 2a

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable and shorter treatment paradigm of approximately two hours The...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 21, 2024

Beckley Psytech
info@beckleypsytech.com
Beckley Park Beckley OXFORD, OX3 9SY United Kingdom

Numinus Wellness Announces Strategic Acquisition of MedBright AI

Plans name change to "Numinus Intelligence" leveraging its current revenue-generating operations to AI-enable mental health clinics across the US The strategic combination merges MedBright's AI-enabled clinical solution capabilities with Numinus'...

Category: Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024

Numinus

Canopy Growth Establishes $250m At-The-Market Programme To Further Enhance the company’s Financial Position And Facilitate Growth

6 June 2024 -- Ontario, Canada -- Canopy Growth Corporation, a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the company has...

Category: Other, Pharmaceutical
Posted: June 6, 2024

Canopy Growth
1 Hershey Drive Smiths Falls, Ontario K7A 0A8